Trial Profile

Anti-fibrotic and molecular aspects of rifaximin in alcoholic liver disease: A randomized placebo controlled clinical trial

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 26 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rifaximin (Primary)
Indications Alcoholic liver disorders
Focus Therapeutic Use

Most Recent Events

08 Nov 2022 Results investigating if self-reported alcohol intake and blood phosphatidyl-ethanol are predictive of changes in liver histology and clinical outcomes in patients with early compensated ALD ,presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases
03 Mar 2022 Status changed from recruiting to completed.
05 Jan 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com